{"id":"W4414446662","doi":"10.1016/j.ejca.2025.115807","title":"First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Trinity College","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Gastroesophageal Junction; Chemotherapy; Interim analysis; Quality of life (healthcare); Interim","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002150207,0.001585914,0.002461132,0.0002801519,0.0003585138,0.001153404,0.0008819317,0.001196451,0.006572115],"category_scores_gemma":[0.001624866,0.0004770128,0.002875548,0.0003097382,0.0008226818,0.001234452,0.0006089645,0.003621662,0.0008305577],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001135636,"about_ca_system_score_gemma":0.0009231441,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001197167,"about_ca_topic_score_gemma":0.003228733,"domain_scores_codex":[0.9993737,0.0003445477,0.00002749197,0.0001047556,0.00003775715,0.0001117046],"domain_scores_gemma":[0.9993393,0.0001708218,0.0001629761,0.00006402323,0.00003632081,0.00022652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9733107,0.002584469,0.0009682893,0.0008631836,0.002557165,0.00003957232,0.00003548451,0.0008283054,0.001338127,0.0001560619,0.002084994,0.01523361],"study_design_scores_gemma":[0.9639545,0.02902526,0.003350334,0.00006798157,0.001669301,0.00005310561,0.00002696014,0.0004259598,0.0002618321,0.0002197207,0.0009305836,0.00001435898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9759906,0.01107927,0.000919453,0.001681777,0.0007583724,0.002050123,0.00360103,0.0001499691,0.003769538],"genre_scores_gemma":[0.983721,0.003641794,0.001250671,0.001676988,0.0003475474,0.002039487,0.003928547,0.00003123455,0.00336274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006572115,"threshold_uncertainty_score":0.02198595,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04052856120843663,"score_gpt":0.3508443201991515,"score_spread":0.3103157589907149,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}